Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients

E Tartour; T Dorval; V Mosseri; L Deneux; C Mathiot; H Brailly; F Montero; I Joyeux; P Pouillart; W H Fridman

doi:10.1038/bjc.1994.175

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients

Br J Cancer. 1994 May;69(5):911-3. doi: 10.1038/bjc.1994.175.

Authors

E Tartour¹, T Dorval, V Mosseri, L Deneux, C Mathiot, H Brailly, F Montero, I Joyeux, P Pouillart, W H Fridman

Affiliation

¹ Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.

Abstract

Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
C-Reactive Protein / metabolism*
Drug Resistance
Female
Humans
Interleukin-2 / therapeutic use*
Interleukin-6 / blood*
Male
Melanoma / blood*
Melanoma / mortality
Melanoma / therapy*
Middle Aged
Prognosis

Substances

Interleukin-2
Interleukin-6
C-Reactive Protein